Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Exact Sciences (EXAS) stock rises as company announces release of data for blood-based cancer test on August 16. Read more ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...